Ana Castro Caldas1, Cristiana Silva2, Luísa Albuquerque3, José Pimentel4, Vanessa Silva5, José Manuel Ferro6. 1. Department of Neurosciences, Serviço de Neurologia, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal. Electronic address: ana_palmela@msn.com. 2. Department of Neurosciences, Serviço de Neurologia, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal. 3. Department of Neurosciences, Serviço de Neurologia, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal; Faculdade de Medicina de Lisboa, University of Lisbon, Lisboa, Portugal. 4. Department of Neurosciences, Serviço de Neurologia, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal; Faculdade de Medicina de Lisboa, University of Lisbon, Lisboa, Portugal; Laboratory of Neuropathology, Department of Neurosciences, Serviço de Neurologia, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal; Instituto de Medicina Molecular, Lisboa, Portugal. 5. Serviço de Neurologia, Hospital Beatriz Ângelo, Loures, Portugal. 6. Department of Neurosciences, Serviço de Neurologia, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal; Faculdade de Medicina de Lisboa, University of Lisbon, Lisboa, Portugal; Instituto de Medicina Molecular, Lisboa, Portugal.
Abstract
INTRODUCTION: Cerebral amyloid angiopathy associated with inflammatory process (CAA-I) is a rare potentially treatable encephalopathy, characterized by an inflammatory response to vascular deposits of β-amyloid. We aimed to describe 3 clinical cases and perform a systematic review of all neuropathologically proved CAA-I case reports to describe its clinical and pathologic features and outcome under different treatments. METHODS: We searched PubMed and Cochrane Library and screened references of included studies and review articles for additional citations. Outcome was classified at the last available follow-up by the modified Rankin Scale (mRS). RESULTS: A total of 67 publications, reporting on 155 patients, were included. Mean age was 66.9 years, and 53.5% were men. The most common clinical presentation was cognitive dysfunction (48.0%) followed by headaches (38.7%), seizures (36.7%), and pyramidal signs (20.0%). Perivascular and vasculitic inflammation with granuloma was the most common pathologic pattern (27.5%). Eighty-six percent were treated with corticosteroids and 33.9% with cyclophosphamide. Forty-two percent regained independence (mRS score 0-2), whereas 20.5% were left with a severe handicap (mRS score 3-5) and 37.5% died. There were no statistically significant differences in outcome between patients treated with therapy with corticosteroids alone comparing with those treated with combination corticosteroids with cytostatic agents. CONCLUSIONS: The most common clinical manifestation of CAA-I was cognitive dysfunction. The functional outcome was unfavorable in the majority of the patients, with death or severe disability in almost two third of the cases, despite treatment. No differences in outcome could be detected between patients treated with corticosteroids versus patients treated with cytostatics, combined with corticosteroids.
INTRODUCTION:Cerebral amyloid angiopathy associated with inflammatory process (CAA-I) is a rare potentially treatable encephalopathy, characterized by an inflammatory response to vascular deposits of β-amyloid. We aimed to describe 3 clinical cases and perform a systematic review of all neuropathologically proved CAA-I case reports to describe its clinical and pathologic features and outcome under different treatments. METHODS: We searched PubMed and Cochrane Library and screened references of included studies and review articles for additional citations. Outcome was classified at the last available follow-up by the modified Rankin Scale (mRS). RESULTS: A total of 67 publications, reporting on 155 patients, were included. Mean age was 66.9 years, and 53.5% were men. The most common clinical presentation was cognitive dysfunction (48.0%) followed by headaches (38.7%), seizures (36.7%), and pyramidal signs (20.0%). Perivascular and vasculitic inflammation with granuloma was the most common pathologic pattern (27.5%). Eighty-six percent were treated with corticosteroids and 33.9% with cyclophosphamide. Forty-two percent regained independence (mRS score 0-2), whereas 20.5% were left with a severe handicap (mRS score 3-5) and 37.5% died. There were no statistically significant differences in outcome between patients treated with therapy with corticosteroids alone comparing with those treated with combination corticosteroids with cytostatic agents. CONCLUSIONS: The most common clinical manifestation of CAA-I was cognitive dysfunction. The functional outcome was unfavorable in the majority of the patients, with death or severe disability in almost two third of the cases, despite treatment. No differences in outcome could be detected between patients treated with corticosteroids versus patients treated with cytostatics, combined with corticosteroids.
Authors: Michelle M Miller-Thomas; Adam L Sipe; Tammie L S Benzinger; Jonathan McConathy; Sarah Connolly; Katherine E Schwetye Journal: Radiographics Date: 2016 Jul-Aug Impact factor: 5.333
Authors: L Grangeon; G Quesney; X Ayrignac; D Wallon; M Verdalle-Cazes; S Coulette; D Renard; A Wacongne; T Allou; N Olivier; Y Boukriche; G Blanchet-Fourcade; P Labauge; C Arquizan; S Canaple; O Godefroy; O Martinaud; P Verdure; M Quillard-Muraine; J Pariente; E Magnin; G Nicolas; C Charbonnier; D Maltête; M Formaglio; N Raposo Journal: J Neurol Date: 2022-06-26 Impact factor: 6.682
Authors: Claudia Uribe Roca; Fabio Maximiliano Gonzalez; Marta Ines Bala; Miguel Saucedo; Lucrecia Bandeo; Luciana Leon Cejas; Sol Pacha; Pablo Bonardo; Carlos Rugilo; Pablo Dezanzo; Rafael Torino; Gustavo Sevlever; Manuel Fernandez Pardal; Ricardo Reisin Journal: Psychiatry Investig Date: 2021-06-17 Impact factor: 2.505
Authors: Björn Reuter; Alexander Venus; Saskia Grudzenski; Patrick Heiler; Lothar Schad; Matthias Staufenbiel; Michael G Hennerici; Marc Fatar Journal: Int J Mol Sci Date: 2016-01-19 Impact factor: 5.923